Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 17/20 | 0.72 |
| ▸ | DRD2 | P14416 | 15/20 | 0.72 |
| ▸ | DRD4 | P21917 | 9/20 | 0.72 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.72 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.72 |
| ▸ | HTR1A | P08908 | 4/20 | 0.72 |
| ▸ | DRD1 | P21728 | 1/20 | 0.69 |
| ▸ | HTR2A | P28223 | 1/20 | 0.69 |
| ▸ | HTR2C | P28335 | 1/20 | 0.69 |
| ▸ | HTR2B | P41595 | 1/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.65 |
| ▸ | FAAH | O00519 | 1/20 | 0.64 |
| ▸ | CNR1 | P21554 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19580027 | 0.82 | DRD3 (0.79) | DRD3DRD2DRD4ADRA1DADRA1A | |
| SCHEMBL30298994 | 0.82 | DRD3 (1.00) | DRD3DRD2DRD4ADRA1DADRA1A | |
| SCHEMBL9650843 | 0.81 | ADRA1D (1.00) | DRD3DRD2DRD4ADRA1DADRA1A | |
| SCHEMBL14761145 | 0.81 | ADRA1D (0.59) | DRD3DRD2DRD4ADRA1DADRA1A | |
| SCHEMBL3408334 | 0.80 | DRD3 (0.77) | DRD3DRD2DRD4ADRA1DADRA1A | |
| SCHEMBL19580065 | 0.79 | DRD3 (0.73) | DRD3DRD2DRD4ADRA1DADRA1A | |
| SCHEMBL30298993 | 0.78 | DRD3 (1.00) | DRD3DRD2DRD4ADRA1DADRA1A | |
| SCHEMBL7344083 | 0.78 | DRD3 (1.00) | DRD3DRD2DRD4ADRA1DADRA1A | |
| SCHEMBL7057990 | 0.78 | DRD3 (0.78) | DRD3DRD2DRD4ADRA1DADRA1A | |
| SCHEMBL7058544 | 0.78 | DRD3 (0.84) | DRD3DRD2DRD4ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785447-B2 | Use of dopamine D3 receptor ligands for the production of drugs for treating renal function disorders | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-22 | — | — | US | claimed |
| US-20060223793-A1 | USE OF DOPAMINE D3 RECEPTOR LIGANDS FOR THE PRODUCTION OF DRUGS FOR TREATING RENAL FUNCTION DISORDERS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2006-10-05 | — | — | US | claimed |
| US-7098214-B1 | Dopamine D3 receptor ligands or antagonists for use in the treatment of renal function disorders | ABBOTT GMBH & CO. KG (DE) | 2006-08-29 | — | — | US | claimed |
| US-8785447-B2 | Use of dopamine D3 receptor ligands for the production of drugs for treating renal function disorders | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-22 | — | — | US | disclosed |
| US-20060223793-A1 | USE OF DOPAMINE D3 RECEPTOR LIGANDS FOR THE PRODUCTION OF DRUGS FOR TREATING RENAL FUNCTION DISORDERS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2006-10-05 | — | — | US | disclosed |
| US-7098214-B1 | Dopamine D3 receptor ligands or antagonists for use in the treatment of renal function disorders | ABBOTT GMBH & CO. KG (DE) | 2006-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223793-A1 | USE OF DOPAMINE D3 RECEPTOR LIGANDS FOR THE PRODUCTION OF DRUGS FOR TREATING RENAL FUNCTION DISORDERS | SLC6A3, DRD3, DRD2 | DRD3 2/4885DRD2 3/4885DRD4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.